scholarly journals Evidence Supporting a Key Role of Lp-PLA2-Generated Lysophosphatidylcholine in Human Atherosclerotic Plaque Inflammation

2012 ◽  
Vol 32 (6) ◽  
pp. 1505-1512 ◽  
Author(s):  
Isabel Gonçalves ◽  
Andreas Edsfeldt ◽  
Na Young Ko ◽  
Helena Grufman ◽  
Katarina Berg ◽  
...  
2016 ◽  
Vol 36 (6) ◽  
pp. 1132-1140 ◽  
Author(s):  
Andreas Edsfeldt ◽  
Pontus Dunér ◽  
Marcus Ståhlman ◽  
Ines G. Mollet ◽  
Giuseppe Asciutto ◽  
...  

2011 ◽  
Vol 32 (2) ◽  
pp. 158-166 ◽  
Author(s):  
Lisa J. Schober ◽  
Anna L. Khandoga ◽  
Suman Dwivedi ◽  
Sandra M. Penz ◽  
Takayuki Maruyama ◽  
...  

2021 ◽  
Vol 83 (3) ◽  
pp. 5
Author(s):  
P.V. Pigarevsky ◽  
R.A. Vorozhbit ◽  
V.A. Snegova ◽  
V.A. Guseva ◽  
S.V. Maltseva ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Tiewei Li ◽  
Xiaojuan Li ◽  
Yichuan Feng ◽  
Geng Dong ◽  
Yuewu Wang ◽  
...  

Matrix metalloproteinase-9 (MMP-9) belongs to the MMP family and has been widely investigated. Excessive MMP-9 expression can enhance extracellular matrix degradation and promote plaque instability. Studies have demonstrated that MMP-9 levels are higher in vulnerable plaques than in stable plaques. Additionally, several human studies have demonstrated that MMP-9 may be a predictor of atherosclerotic plaque instability and a risk factor for future adverse cardiovascular and cerebrovascular events. MMP-9 deficiency or blocking MMP-9 expression can inhibit plaque inflammation and prevent atherosclerotic plaque instability. All of these results suggest that MMP-9 may be a useful predictive biomarker for vulnerable atherosclerotic plaques, as well as a therapeutic target for preventing atherosclerotic plaque instability. In this review, we describe the structure, function, and regulation of MMP-9. We also discuss the role of MMP-9 in predicting and preventing atherosclerotic plaque instability.


Author(s):  
Joshua J. Man ◽  
Qing Lu ◽  
M. Elizabeth Moss ◽  
Brigett Carvajal ◽  
Wendy Baur ◽  
...  

Objective: MR (mineralocorticoid receptor) activation associates with increased risk of cardiovascular ischemia while MR inhibition reduces cardiovascular-related mortality and plaque inflammation in mouse atherosclerosis. MR in myeloid cells (My-MR) promotes inflammatory cell infiltration into injured tissues and atherosclerotic plaque inflammation by unclear mechanisms. Here, we examined the role of My-MR in leukocyte trafficking and the impact of sex. Approach and Results: We confirm in vivo that My-MR deletion (My-MR-KO) in ApoE-KO mice decreased plaque size. Flow cytometry revealed fewer plaque macrophages with My-MR-KO. By intravital microscopy, My-MR-KO significantly attenuated monocyte slow-rolling and adhesion to mesenteric vessels and decreased peritoneal infiltration of myeloid cells in response to inflammatory stimuli in male but not female mice. My-MR-KO mice had significantly less PSGL1 (P-selectin glycoprotein ligand 1) mRNA in peritoneal macrophages and surface PSGL1 protein on circulating monocytes in males. In vitro, MR activation with aldosterone significantly increased PSGL1 mRNA only in monocytes from MR-intact males. Similarly, aldosterone induced, and MR antagonist spironolactone inhibited, PSGL1 expression in human U937 monocytes. Mechanistically, aldosterone stimulated MR binding to a predicted MR response element in intron-1 of the PSGL1 gene by ChIP-qPCR. Reporter assays demonstrated that this PSGL1 MR response element is necessary and sufficient for aldosterone-activated, MR-dependent transcriptional activity. Conclusions: These data identify PSGL1 as a My-MR target gene that drives leukocyte trafficking to enhance atherosclerotic plaque inflammation. These novel and sexually dimorphic findings provide insight into increased ischemia risk with MR activation, cardiovascular protection in women, and the role of MR in atherosclerosis and tissue inflammation.


2004 ◽  
Vol 43 (5) ◽  
pp. A506
Author(s):  
Tomasz Mazurek ◽  
LiFeng Zhang ◽  
Andrew Zalewski ◽  
Mark Kahn ◽  
Anthony Carabasi ◽  
...  

2015 ◽  
Vol 241 (1) ◽  
pp. e30
Author(s):  
A. Edsfeldt ◽  
P. Dunér ◽  
M. Ståhlman ◽  
I.G. Mollet ◽  
G. Asciutto ◽  
...  

2020 ◽  
Vol 26 (34) ◽  
pp. 4234-4245
Author(s):  
Deepaneeta Sarmah ◽  
Aishika Datta ◽  
Swapnil Raut ◽  
Ankan Sarkar ◽  
Birva Shah ◽  
...  

Inflammation is a devastating outcome of cerebrovascular diseases (CVD), namely stroke and atherosclerosis. Numerous studies over the decade have shown that inflammasomes play a role in mediating inflammatory reactions post cellular injury occurring after a stroke or a rupture of an atherosclerotic plaque. In view of this, targeting these inflammatory pathways using different pharmacological therapies may improve outcomes in patients with CVD. Here, we review the mechanisms by which inflammasomes drive the pathogenesis of stroke and atherosclerosis. Also, discussed here are the possible treatment strategies available for inhibiting inflammasomes or their up-stream/down-stream mediators.


Sign in / Sign up

Export Citation Format

Share Document